Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study

Pembrolizumab demonstrated durable antitumor activity in patients with previously treated, advanced microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR) tumors, including endometrial cancer, in the nonrandomized, open-label, multicohort, phase II KEYNOTE-158 study (NCT02628067)....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology Jg. 40; H. 7; S. 752
Hauptverfasser:	O'Malley, David M, Bariani, Giovanni Mendonca, Cassier, Philippe A, Marabelle, Aurelien, Hansen, Aaron R, De Jesus Acosta, Ana, Miller, Jr, Wilson H, Safra, Tamar, Italiano, Antoine, Mileshkin, Linda, Xu, Lei, Jin, Fan, Norwood, Kevin, Maio, Michele
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 01.03.2022
Schlagworte:	Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents, Immunological - therapeutic use Biomarkers, Tumor - genetics DNA Mismatch Repair Endometrial Neoplasms - drug therapy Endometrial Neoplasms - genetics Endometrial Neoplasms - pathology Female Follow-Up Studies Humans Microsatellite Instability Middle Aged Non-Randomized Controlled Trials as Topic Prognosis Retrospective Studies Survival Rate
ISSN:	1527-7755, 1527-7755
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!